دورية أكاديمية
أعرض في EDS

Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.

التفاصيل البيبلوغرافية
العنوان: Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
المؤلفون: Funt SA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA., Knezevic A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wilson K; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Bromberg M; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Budnick A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., O'Connor KL; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., McHugh DJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA., Larsen E; Formerly of Decibel Therapeutics, Boston, Massachusetts, USA., Bajorin DF; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA., Motzer RJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA., Tonorezos ES; National Cancer Institute, Rockville, Maryland, USA., Patil S; Department of Biostatistics, Cleveland Clinic, Cleveland, Ohio, USA., Feldman DR; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA.
المصدر: Cancer [Cancer] 2023 Dec 15; Vol. 129 (24), pp. 3952-3961. Date of Electronic Publication: 2023 Sep 16.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
مواضيع طبية MeSH: Ototoxicity*/etiology , Neoplasms, Germ Cell and Embryonal*/drug therapy , Neoplasms, Germ Cell and Embryonal*/etiology , Hearing Loss*/chemically induced , Hearing Loss*/epidemiology, Male ; Adolescent ; Young Adult ; Humans ; Adult ; Carboplatin/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
مستخلص: Background: High-dose carboplatin is an essential part of curative high-dose chemotherapy (HDCT) for patients with previously treated germ cell tumors (GCTs). Although hearing loss (HL) is a known side effect of HDCT, data on its severity and characteristics are limited.
Methods: Eligible patients received HDCT for GCTs from 1993 to 2017 and had audiograms before and after HDCT. HL severity was classified by American Speech-Language-Hearing Association criteria, and mean change in hearing threshold at each frequency (0.25-8 kHz) was estimated from pre- to post-HDCT and between HDCT cycles.
Results: Of 115 patients (median age, 32 years), 102 (89%) received three cycles of HDCT. Of 106 patients with normal hearing to mild HL in the speech frequencies (0.5-4 kHz) before HDCT, 70 (66%) developed moderate to profound HL in the speech frequencies after HDCT. Twenty-five patients (22%) were recommended for hearing aids after HDCT. Patients with moderate to profound HL isolated to the higher frequencies (6-8 kHz) before HDCT were more likely to develop moderate to profound HL in the speech frequencies after HDCT (94% vs. 61%; p = .01) and to be recommended for hearing aids (39% vs. 18%; p = .05).
Conclusions: HL was frequent after HDCT for GCTs, with most patients developing at least moderate HL in the speech frequencies and approximately one in five recommended for hearing aids. Moderate to profound HL isolated to high frequencies at baseline was predictive of more clinically significant hearing impairment after HDCT.
Plain Language Summary: Some patients with germ cell tumors, the most common malignancy in adolescent and young adult men, are not cured with standard-dose chemotherapy and require high-dose chemotherapy (HDCT). Using detailed hearing assessments of patients receiving HDCT, we found that most patients developed significant hearing loss and that one in five needed hearing aids. Thus, strategies to reduce this side effect are urgently needed, and all patients receiving HDCT should have a hearing test after therapy.
(© 2023 American Cancer Society.)
References: Clin Genitourin Cancer. 2015 Oct;13(5):453-60. (PMID: 26072101)
N Engl J Med. 2018 Jun 21;378(25):2376-2385. (PMID: 29924955)
J Clin Oncol. 2012 Mar 10;30(8):800-5. (PMID: 22291076)
Clin Pharmacol Ther. 2013 Aug;94(2):243-51. (PMID: 23588304)
J Clin Oncol. 2010 Apr 1;28(10):1706-13. (PMID: 20194867)
Pharmacogenomics. 2008 Oct;9(10):1521-30. (PMID: 18855538)
J Clin Oncol. 2020 Aug 10;38(23):2639-2646. (PMID: 32463737)
J Clin Oncol. 2021 May 10;39(14):1563-1574. (PMID: 33822655)
Front Cell Neurosci. 2019 Jul 09;13:300. (PMID: 31338024)
Cancer Med. 2021 Apr;10(7):2250-2258. (PMID: 33675184)
Pediatr Blood Cancer. 2018 May;65(5):e26931. (PMID: 29350448)
J Clin Oncol. 2023 Apr 20;41(12):2211-2226. (PMID: 36626694)
Nat Genet. 2009 Dec;41(12):1345-9. (PMID: 19898482)
Br J Cancer. 1996 Apr;73(8):979-84. (PMID: 8611435)
J Clin Oncol. 2017 Apr 1;35(10):1096-1102. (PMID: 27870561)
J Cancer Surviv. 2023 Feb;17(1):27-39. (PMID: 36637632)
Eur J Cancer. 2004 Nov;40(16):2445-51. (PMID: 15519518)
J Clin Oncol. 2007 Apr 1;25(10):1190-5. (PMID: 17401008)
World J Urol. 2015 May;33(5):623-31. (PMID: 25030752)
J Clin Oncol. 2004 Mar 15;22(6):1158; author reply 1158-9. (PMID: 15020620)
Cancer Res. 1996 Feb 15;56(4):706-9. (PMID: 8630999)
N Engl J Med. 2007 Jul 26;357(4):340-8. (PMID: 17652649)
J Clin Oncol. 2007 Jul 1;25(19):2778-84. (PMID: 17602082)
J Clin Oncol. 2012 Apr 1;30(10):1034-41. (PMID: 22370329)
Cancer. 2020 Apr 15;126(8):1776-1783. (PMID: 31899553)
Clin Cancer Res. 2017 Dec 1;23(23):7171-7179. (PMID: 28928162)
Clin Cancer Res. 2001 Mar;7(3):493-500. (PMID: 11297239)
Clin Cancer Res. 2019 Feb 15;25(4):1147-1155. (PMID: 30305294)
J Clin Oncol. 2000 Mar;18(6):1173-80. (PMID: 10715285)
J Clin Oncol. 2016 Aug 10;34(23):2712-20. (PMID: 27354478)
J Clin Oncol. 2005 May 20;23(15):3649-50; author reply 3650-1. (PMID: 15908692)
World J Urol. 2004 Apr;22(1):2-14. (PMID: 15034740)
J Pharmacol Exp Ther. 1998 Jul;286(1):77-84. (PMID: 9655844)
Lancet Oncol. 2017 Jan;18(1):63-74. (PMID: 27914822)
J Clin Oncol. 2021 May 10;39(14):1553-1562. (PMID: 33729863)
J Cancer. 2011;2:374-7. (PMID: 21750688)
J Clin Oncol. 2007 Jan 1;25(1):85-90. (PMID: 17194908)
Front Neurosci. 2022 May 24;16:867453. (PMID: 35685768)
J Clin Oncol. 1997 Feb;15(2):594-603. (PMID: 9053482)
Bone Marrow Transplant. 1998 Oct;22(7):669-74. (PMID: 9818694)
Int J Otolaryngol. 2011;2011:937861. (PMID: 22121370)
Invest New Drugs. 2020 Oct;38(5):1463-1471. (PMID: 32157599)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS; R25CA020449 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: cancer treatment; germ cell tumor; hearing loss; high-dose carboplatin; ototoxicity; survivorship
المشرفين على المادة: BG3F62OND5 (Carboplatin)
تواريخ الأحداث: Date Created: 20230916 Date Completed: 20231218 Latest Revision: 20240808
رمز التحديث: 20240808
مُعرف محوري في PubMed: PMC11305123
DOI: 10.1002/cncr.34991
PMID: 37715631
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-0142
DOI:10.1002/cncr.34991